Kesimpta reduces relapses, brain lesions for up to 5 years: Study
Up to five years of treatment with Kesimpta (ofatumumab) continues to keep the number of relapses and brain lesions…
Articles by Margarida Maia, PhD
Ocrevus keeps MS activity stable after stopping Tysabri: Study
Switching from Tysabri (natalizumab) to Ocrevus (ocrelizumab) does not appear to increase disease activity in people with relapsing…
Early use of high-efficacy DMTs may keep patients on therapy longer
Starting treatment with a high-efficacy disease-modifying therapy (DMT), rather than one with lesser efficacy, may reduce the number of…
Education found to help with MS treatment adherence in Iran
An educational intervention program was found to help improve treatment adherence among people with multiple sclerosis (MS) receiving injectable…
For women with MS, finding coping strategies for sex is more satisfying
The sexual satisfaction of women with multiple sclerosis (MS) improved when they actively sought out ways to deal with…
FDA clears way for Phase 1 study of PIPE-791 in healthy volunteers
Pipeline Therapeutics will soon launch a Phase 1 clinical study to test PIPE-791, one of its candidate treatments for…
Stress in MS linked to worse disability, more burden in US survey
Being exposed to stress as children or adults makes it more likely that people with multiple sclerosis (MS) will…
Fertility rates about 2 times lower in women with MS: Study in Italy
While fertility rates in women with multiple sclerosis (MS) have been increasing over time, they remain about two times…
1st group of healthy volunteers dosed in Phase 1 trial of ‘Lucid-MS’
FSD Pharma has completed dosing in the first group of healthy volunteers enrolled in its Phase 1 clinical trial…
Myeloid cells with added ‘backpack’ may help halt MS inflammation
Attaching a kind of molecule backpack to myeloid cells — a type of immune cells involved in the inflammatory…
Region in Japan sees steady increase in MS prevalence over 20 years
Tokachi, a region in northern Japan, has seen a steady increase in the prevalence or proportion of people in the…
First participant completes dosing in Phase 1 Lucid-MS trial
The first participant has completed dosing in a Phase 1 clinical trial testing FSD Pharma‘s Lucid-21-302, an experimental oral…
Vitamin D at high dose doesn’t lower MS relapse risk, Phase 3 trial finds
A high-dose vitamin D supplement did not reduce the risk of relapses in people with relapsing-remitting multiple sclerosis…
Lemtrada aids cognitive skills, eases depression in real-world MS study
One year of treatment with Lemtrada (alemtuzumab) significantly improved cognitive abilities, particularly with processing speed, and eased depression in…
Women with MS at higher risk of having premature, smaller babies
Women with multiple sclerosis (MS) may have a higher risk of giving birth to premature or smaller babies, but…
CHMP favors Briumvi for approval to treat relapsing forms of MS in EU
An arm of the European Medicines Agency favors the approval of Briumvi (ublituximab) to treat adults with active, relapsing…
Sensoready Pen easier to use for MS therapy than other devices: Survey
Both people with multiple sclerosis (MS) and their nurses prefer the Sensoready Pen for administering Kesimpta (ofatumumab) —…
Tiziana to launch clinical trial for MS therapy foralumab in late 2023
Tiziana Life Sciences plans to launch a Phase 2 clinical trial to investigate its foralumab nasal spray in people…
Early MS MRI markers linked to worse disability in 10 years time
MRI scans of the brain acquired early on after the onset of multiple sclerosis (MS) may help predict…
Adult diagnostic criteria lacking at predicting future MS in children
Predicting whether an asymptomatic child or adolescent with signs of demyelination on imaging scans will develop multiple sclerosis…
No rise in MS patients’ risk of relapse seen with fertility treatments
Disease relapses are no more likely in women with multiple sclerosis (MS) after fertility treatment than they were before…
Higher blood levels of Ocrevus lower confirmed disability progression risk
Higher blood levels of Ocrevus (ocrelizumab) is associated with a significantly lower risk of confirmed disability progression during treatment…
Phase 2 trial to determine if low-dose ketamine eases MS fatigue
A Phase 2 clinical trial evaluating whether a low dose of ketamine can ease fatigue in people with multiple sclerosis…
Frequency moving to test agents with remyelination potential
Frequency Therapeutics announced that it is shifting its focus to advancing small molecules that aim to restore myelin, the protective…
Dietitian advice assists MS patients to improve calcium intake: Trial
A tailored diet plan from a dietitian may help people with multiple sclerosis (MS) ingest more calcium from foods,…
Crowdfunding Campaign Launched for MS, Other Clinical Programs
FibroBiologics has launched an online crowdfunding campaign to support the development of potential therapies in the company’s pipeline and advance…
Aubagio Significantly Lowers Plasma NfL Levels in TERIKIDS Trial
Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children…
MS Relapse, Worse Disease More Likely for Smokers: New Study
People with relapsing-remitting multiple sclerosis (RRMS) who are receiving oral disease-modifying therapies (DMTs) are still…
MS Comorbidities Lead to Economic Burden for Patients, Study Finds
About half of all individuals diagnosed with multiple sclerosis (MS) have at least one other co-occurring medical disorder, and…
No Increase in Disease Activity With Longer Lag in Rituximab Treatment
People with relapsing-remitting multiple sclerosis (RRMS) who are stable on rituximab treatment may receive the therapy at extended…